This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Helicos BioSciences Expands Its License With Arizona Technology Enterprises Covering Next Generation Sequencing; New Patents Continue To Issue

Helicos BioSciences Corporation (OTCQB: HLCS.PK) announced today that it has amended its existing license with Arizona Technology Enterprises (AzTE) to include all activities that fall within the scope of, or constitute the practice of, the licensed patents, and gives Helicos full and unencumbered rights to the associated intellectual property. The license, which gives Helicos rights to several patents covering sequencing-by-synthesis methods, now expressly includes detection methods that do not rely on optically-labeled nucleotides.

“The expanded license is another example of Helicos’s successful strategy of systematically expanding its IP portfolio. The newly acquired rights will be an important asset in our licensing and IP monetization efforts that include the active litigation announced previously.” stated Dr. Ivan Trifunovich, President and CEO of Helicos. “In addition to the expanded license, Helicos continues to increase the depth and breadth of company’s patent estate through newly issued patents and a large number of important patent applications in process. As we witness the rapid expansion of next generation sequencing applications covered by our patents in the research and molecular diagnostic (MDx) fields, we intend to maximize the return to our stakeholders through a licensing program and IP enforcement mechanisms.” continued Dr. Trifunovich.

In 2011, 8 Helicos’s patents were issued or allowed, and more than a dozen patent applications were filed. For example, U.S. patent No. 7,875,440 (currently the subject of an inter parties reexamination by the USPTO based upon the request of Life Technologies Corporation), entitled “Method of determining the nucleotide sequence of oligonucleotides and DNA molecules”, which derives from an existing foundational invention with a very early priority date of May 1998, and U.S. patent No. 7,897,345 entitled “Short Cycle Methods for Sequencing Polynucleotides”. Both patents contain very broad claims that cover the very core chemistry of most major next generation sequencing platforms. Another example is U.S. patent 7,948,625, titled “Apparatus and Methods for Analyzing Samples”, which covers instrument claims on a lighting system for detecting samples that includes 2 light sources.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,472.37 +200.36 1.23%
S&P 500 1,951.36 +27.54 1.43%
NASDAQ 4,707.7750 +80.6910 1.74%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs